Latest news in cancer
CAR-T therapy, CAR-T technology, what are CAR-T cell immunotherapy ? CAR-T treatment cost, latest CAR-T clinical trial recruitment
March 2022: CAR-T therapy, CAR-T technology, what are CAR-T cell immunotherapy ? CAR-T treatment price, cost, the latest CAR-T clinical trial recruitment...
Olaparib is approved for adjuvant treatment of high-risk early breast cancer
March 2022: The Food and Drug Administration has approved olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) for the adjuvant treatment of adult patients...
Neoadjuvant nivolumab and platinum-doublet chemotherapy is approved for early-stage non-small cell lung cancer
March 2022: In the neoadjuvant setting, the FDA approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with platinum-doublet chemotherapy...
Ciltacabtagene autoleucel is approved for relapsed or refractory multiple myeloma
March 2022: After four or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal...
Tebentafusp-tebn is approved for unresectable or metastatic uveal melanoma
March 2022: Tebentafusp-tebn (Kimmtrak, Immunocore Limited), a bispecific gp100 peptide-HLA-directed CD3 T cell engager, has been licenced by the Food and Drug...
Abatacept is approved for prophylaxis of acute graft versus host disease
March 2022: Abatacept (Orencia, Bristol-Myers Squibb Company) has been approved by the Food and Drug Administration for the prevention of acute graft versus...
Study suggest CAR T-Cell therapy effective as first line treatment for high risk large B-cell lymphoma
March 2022: The University of Texas MD Anderson Cancer Center researchers discovered that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR...
Rituximab plus chemotherapy is approved by FDA for pediatric cancer indications
March 2022: The Food and Drug Administration has approved rituximab (Rituxan, Genentech, Inc.) in conjunction with chemotherapy for CD20-positive diffuse...
Darzalex faspro, kyprolis, and dexamethasone is approved by FDA for multiple myeloma
March 2022: Daratumumab + hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) and carfilzomib (Kyprolis, Amgen, Inc.) plus dexamethasone have been...
Effectiveness of CAR T-Cell therapy against high risk large B-Cell lymphoma
Dec 2020: The University of Texas MD Anderson Cancer Center researchers discovered that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell...
CAR T-Cell therapy for childhood brain tumor
Dec 2021: CAR T-Cell therapy is currently approved for some forms of leukemia, lymphoma, and multiple myeloma. Researchers have now also developed the...
Patient in China achieves complete remission from leukemia after CAR T-Cell therapy
Feb 2022: In China, a patient whose life was on the verge of ending was entirely healed of leukaemia thanks to CAR T-cell therapy, which stimulated the immune...
China-based CAR-T Cell therapy achieves breakthrough clinical trial results
June 2016: Professor Huang He of Zhejiang University’s First Affiliated Hospital presented the outcomes of 10 clinical cases, including CAR-T cell...
CAR T-Cell therapy saves leukemia patient in China
Feb 2022: A 12-year-old girl from southwest China’s Chongqing Municipality was saved by an unconventional therapy instead of chemotherapy or...
World Cancer Day 2022
4th Feb 2022: In India, cancer can have serious social and economic effects, typically resulting in family destitution and societal injustice. In this...
Pafolacianine is approved for identifying malignant ovarian cancer lesions
Jan 2022: Pafolacianine (Cytalux, On Target Laboratories, LLC), an optical imaging agent, has been licenced by the Food and Drug Administration for adult...
Sirolimus protein-bound particles is approved for malignant perivascular epithelioid cell tumor
Jan 2022: For adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumours, the Food and Drug...
Pembrolizumab is approved for adjuvant treatment of renal cell carcinoma
Jan 2022: Pembrolizumab (Keytruda, Merck) has been approved by the Food and Drug Administration for the adjuvant treatment of patients with renal cell...
Drugs approved for treatment of liver cancer
Dec 2021: The following drugs are approved as of date for the treatment of liver cancer:. Please check the prescribing information before taking the drug....
Asciminib is approved for Philadelphia chromosome-positive chronic myeloid leukemia
Nov 2021: Asciminib (Scemblix, Novartis AG) was given accelerated approval by the Food and Drug Administration for patients with Philadelphia...
Atezolizumab is approved by FDA as adjuvant treatment for non-small cell lung cancer
Nov 2021: The Food and Drug Administration has approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment in patients with stage II to IIIA...
Pembrolizumab combination is approved by FDA for the first-line treatment of cervical cancer
Nov 2021: Pembrolizumab (Keytruda, Merck) in conjunction with chemotherapy, with or without bevacizumab, has been approved by the Food and Drug Administration...
Abemaciclib is approved by FDA with endocrine therapy for early breast cancer
October 2021: The Food and Drug Administration has approved abemaciclib (Verzenio, Eli Lilly and Company) in combination with endocrine therapy (tamoxifen or...
Brexucabtagene autoleucel is approved by FDA for relapsed or refractory B-cell precursor acute lymphoblastic leukemia
October 2021: Brexucabtagene autoleucel (Tecartus, Kite Pharma, Inc.) has been approved by the Food and Drug Administration for adult patients with relapsed or...
Ruxolitinib is approved for chronic graft-versus-host disease
October 2021: After failure of one or two lines of systemic therapy, the Food and Drug Administration approved ruxolitinib (Jakafi, Incyte Corp.) for chronic...
Tisotumab forvedotin-tftv is approved for recurrent or metastatic cervical cancer
October 2021: The FDA has given tisotumab vedotin-tftv (Tivdak, Seagen Inc.), a tissue factor-directed antibody and microtubule inhibitor combination, rapid...
Cabozantinib is approved for differentiated thyroid cancer
October 2021: Cabozantinib (Cabometyx, Exelixis, Inc.) has been approved by the Food and Drug Administration for adult and paediatric patients 12 years of age...
The FDA has given mobocertinib expedited approval for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations
September 2021: The FDA granted accelerated approval to mobocertinib (Exkivity, Takeda Pharmaceuticals, Inc.) for adult patients with locally advanced or...
The FDA has approved zanubrutinib for the treatment of Waldenstrom’s macroglobulinemia
September 2021: For adult patients with Waldenström’s macroglobulinemia, the FDA has approved zanubrutinib (Brukinsa, BeiGene) (WM). In ASPEN...
Ivosidenib has been approved by the FDA for advanced or metastatic cholangiocarcinoma
Sept 19, 2021: The Food and Drug Administration approved Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) for adult patients with previously treated, locally...
TECARTUS (brexucabtagene autoleucel) – CAR T treatment for relapsed or refractory mantle cell lymphoma
July 25, 2021: Kite, a Gilead Company (Nasdaq: GILD), today announced that the FDA has granted TecartusTM (brexucabtagene autoleucel, formerly KTE-X19), the...
Nivolumab has been approved by the FDA for use as an adjuvant treatment for urothelial carcinoma
August 2021: Nivolumab (Opdivo, Bristol-Myers Squibb Co.) has been approved by the Food and Drug Administration for the adjuvant treatment of patients with...
Dostarlimab-gxly receives accelerated approval from the FDA for dMMR advanced solid tumours
August 2021: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given accelerated approval by the Food and Drug Administration for adult patients with...
Belzutifan has been approved by the FDA for malignancies linked to von Hippel-Lindau disease
August 2021: Belzutifan (Welireg, Merck), a hypoxia-inducible factor inhibitor, has been approved by the Food and Drug Administration for adult patients with...
The FDA has approved the combination of lenvatinib and pembrolizumab for advanced renal cell carcinoma
August 2021: The combination of lenvatinib (Lenvima, Eisai) and pembrolizumab (Keytruda, Merck) has been approved by the Food and Drug Administration for the...
Pembrolizumab has been approved by the FDA for high-risk early-stage triple-negative breast cancer
August 2021: Pembrolizumab (Keytruda, Merck) was approved by the FDA for high-risk, early-stage triple-negative breast cancer (TNBC) as a neoadjuvant treatment...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.